Structure of Navitoclax
CAS No.: 923564-51-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Navitoclax (ABT-263) is an orally active Bcl-2 inhibitor that binds to multiple Bcl-2 family proteins with Ki values of less than 1 nM.
Synonyms: ABT-263; A-855071
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 923564-51-6 |
Formula : | C47H55ClF3N5O6S3 |
M.W : | 974.61 |
SMILES Code : | O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4 |
Synonyms : |
ABT-263; A-855071
|
MDL No. : | MFCD12756219 |
InChI Key : | JLYAXFNOILIKPP-KXQOOQHDSA-N |
Pubchem ID : | 24978538 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
H1975 cells | 500 nM | 48 h | To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. | PMC9246391 |
A014 cells | 500 nM | 48 h | To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. | PMC9246391 |
PC-9 cells | 500 nM | 48-72 h | To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. | PMC9246391 |
H3255 cells | 500 nM | 48-72 h | To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. | PMC9246391 |
MPM cells | 1 µM | 18-24 h | To evaluate the apoptotic priming effect of Navitoclax in combination with AZD8055 on MPM cells, results showed that the combination significantly enhanced apoptosis. | PMC10199949 |
De-iniDCs | 1, 5, 10 μM | overnight | To evaluate the effect of Navitoclax on DC antigen presentation, results showed that Navitoclax enhanced the antigen presentation capability of DCs. | PMC7615270 |
Liv7k oral cancer cell line | 10 µM | 72 h | To test the growth inhibition effect of drugs under hypoxic and normoxic conditions, results showed that drugs with high cSL-scores exhibited stronger drug response in each condition separately. | PMC6026173 |
MDA-MB-231 cells | 10 µM | 3 days | To evaluate the effect of Navitoclax retreatment, it was found that cells remained sensitive to the drug upon retreatment. | PMC8154902 |
MDA-MB-231 cells | 10 µM | 3 days | To evaluate the cytotoxic effect of Navitoclax on MDA-MB-231 cells, it was found that cells were highly sensitive to 72 h treatment but fully recovered after 10 days in drug-free media. | PMC8154902 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | Sf3b1 K700E conditional knock-in mice | Oral gavage | 25 mg/kg | 5 days per week for two weeks | Test the combination effect of Navitoclax with Eltanexor, showing preferential sensitivity for SF3B1 mutant cells without excessive toxicity. | PMC11347370 |
Mice | H1975 subcutaneous xenografts | Oral | 50 mg/kg | Daily for 14 days | To evaluate the therapeutic effect of Navitoclax and Osimertinib combination therapy on RBM10-deficient EGFR-mutant tumors, results showed that the combination significantly increased tumor apoptosis. | PMC9246391 |
Mice | TNBC-PDX model | Oral | 100 mg/kg | Once daily for 21 days | To evaluate the tumor growth inhibitory effect of Navitoclax in combination with Metformin in TNBC-PDX model mice, results showed that the combination significantly inhibited tumor growth and extended survival. | PMC6365524 |
Mice | MPM PDX model | Oral | 100 mg/kg | Once daily for 21 days | To evaluate the efficacy of Navitoclax in combination with AZD8055 in the MPM PDX model, results showed that the combination significantly reduced tumor volume and increased mouse survival. | PMC10199949 |
Mice | Orthotopic MCA205 fibrosarcoma model | Intraperitoneal injection | 50 mg/kg | Day 0 and day 2 | To evaluate the activation of cDC1 cells by Navitoclax, results showed that Navitoclax significantly upregulated the activation markers of cDC1 cells. | PMC7615270 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01423539 | Diffuse Large B-Cell Lymphoma | Phase 2 | Withdrawn(The NAVIGATE study h... More >>as been terminated due to non-safety related reasons.) Less << | February 2014 | United States, California ... More >> Fountain Valley, California, United States, 92708 United States, Florida Hudson, Florida, United States, 34667 United States, Georgia Lawrenceville, Georgia, United States, 30045 United States, Illinois Centralia, Illinois, United States, 62801 Harvey, Illinois, United States, 60426 United States, Indiana Terre Haute, Indiana, United States, 47802 United States, Kentucky Hazard, Kentucky, United States, 41701 Paducah, Kentucky, United States, 42003 United States, Maryland Rockville, Maryland, United States, 20850 United States, Missouri Jefferson City, Missouri, United States, 65109 United States, Montana Great Falls, Montana, United States, 59405 United States, Ohio Newark, Ohio, United States, 43055 United States, Tennessee Nashville, Tennessee, United States, 37203 Less << |
NCT01053520 | Healthy Female Subjects | Phase 1 | Completed | - | United States, Illinois ... More >> Site Reference ID/Investigator# 23602 Waukegan, Illinois, United States, 60085 Less << |
NCT01989585 | BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << | Phase 1 Phase 2 | Recruiting | - | United States, California ... More >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Janice M. Mehnert United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: Kari L. Kendra United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Michael A. Davies Less << |
NCT02520778 | EGFR Activating Mutation ... More >> EGFR Exon 19 Deletion Mutation EGFR NP_005219.2:p.G719X EGFR NP_005219.2:p.L858R EGFR NP_005219.2:p.L861Q EGFR NP_005219.2:p.T790M Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << | Phase 1 | Recruiting | - | United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Jonathan W. Riess United States, Colorado University of Colorado Hospital Active, not recruiting Aurora, Colorado, United States, 80045 United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact 800-456-7121 canceranswers@moffitt.org Principal Investigator: Eric B. Haura United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Site Public Contact 404-778-1868 Principal Investigator: Suchita Pakkala United States, Kentucky University of Kentucky/Markey Cancer Center Active, not recruiting Lexington, Kentucky, United States, 40536 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Christine L. Hann United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Geoffrey R. Oxnard Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Geoffrey R. Oxnard United States, New Jersey Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Jyoti Malhotra Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Jyoti Malhotra United States, North Carolina UNC Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Site Public Contact 877-668-0683 cancerclinicaltrials@med.unc.edu Principal Investigator: Jared M. Weiss Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: Erin M. Bertino United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Liza C. Villaruz United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: Site Public Contact 434-243-6303 PAS9E@virginia.edu Principal Investigator: Ryan D. Gentzler Less << |
NCT02079740 | Advanced Malignant Solid Neopl... More >>asm KRAS Gene Mutation Metastatic Malignant Solid Neoplasm NRAS Gene Mutation Recurrent Colorectal Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Colorectal Cancer AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Malignant Neoplasm Less << | Phase 1 Phase 2 | Recruiting | - | United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Suspended Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ryan B. Corcoran 877-726-5130 Principal Investigator: Ryan B. Corcoran Less << |
NCT03366103 | Metastatic Malignant Solid Neo... More >>plasm Recurrent Malignant Solid Neoplasm Recurrent Small Cell Lung Carcinoma Stage III Small Cell Lung Carcinoma AJCC v7 Stage IIIA Small Cell Lung Carcinoma AJCC v7 Stage IIIB Small Cell Lung Carcinoma AJCC v7 Stage IV Small Cell Lung Carcinoma AJCC v7 Unresectable Solid Neoplasm Less << | Phase 1 Phase 2 | Recruiting | May 31, 2020 | United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Christine L. Hann United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Anna F. Farago Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Anna F. Farago Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Anna F. Farago Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Anna F. Farago United States, New Jersey Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Site Public Contact 212-639-7592 Principal Investigator: Wei-Chu V. Lai Less << |
NCT00445198 | Small Cell Lung Cancer|Small C... More >>ell Lung Carcinoma Less << | PHASE1|PHASE2 | COMPLETED | 2025-12-10 | Site Reference ID/Investigator... More >># 13605, Peoria, Arizona, 85381, United States|Site Reference ID/Investigator# 5261, Phoenix, Arizona, 85013, United States|Site Reference ID/Investigator# 11942, Los Angeles, California, 90095-7187, United States|Site Reference ID/Investigator# 4718, Sacramento, California, 95817, United States|Site Reference ID/Investigator# 3755, Aurora, Colorado, 80045-0510, United States|Site Reference ID/Investigator# 8324, Atlanta, Georgia, 30322, United States|Site Reference ID/Investigator# 2623, Chicago, Illinois, 60612, United States|Site Reference ID/Investigator# 2625, Baltimore, Maryland, 21231-1000, United States|Site Reference ID/Investigator# 12343, Bethesda, Maryland, 20892, United States|Site Reference ID/Investigator# 11941, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 2626, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 4934, Charlotte, North Carolina, 28204, United States|Site Reference ID/Investigator# 2624, Nashville, Tennessee, 37203, United States|Site Reference ID/Investigator# 6650, Tacoma, Washington, 98405, United States|Site Reference ID/Investigator# 7493, Edmonton, T6G 1Z2, Canada|Site Reference ID/Investigator# 7635, Ottawa, K1H 8L6, Canada|Site Reference ID/Investigator# 18541, Leicester, LE1 5WW, United Kingdom|Site Reference ID/Investigator# 2622, Manchester, M20 4BX, United Kingdom Less << |
NCT00982566 | Lymphoid Malignancy ... More >> Solid Tumors Less << | Phase 1 | Completed | - | - |
NCT00481091 | Chronic Lymphocytic Leukemia | PHASE1|PHASE2 | COMPLETED | 2022-05-12 | Moores Cancer Center at UC San... More >> Diego /ID# 5566, La Jolla, California, 92093, United States|Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, 02215, United States|University of Nebraska Medical Center /ID# 12261, Omaha, Nebraska, 68198, United States|North Shore University Hospital /ID# 12267, New Hyde Park, New York, 11040, United States|University of Texas MD Anderson Cancer Center /ID# 5575, Houston, Texas, 77030, United States|Northwest Medical Specialties - Tacoma /ID# 26428, Tacoma, Washington, 98405, United States|Peter MacCallum Cancer Ctr /ID# 6583, Melbourne, Victoria, 3000, Australia|The Royal Melbourne Hospital /ID# 5576, Parkville, Victoria, 3050, Australia|Universitaetsklinikum Koeln /ID# 5924, K?ln, Nordrhein-Westfalen, 50937, Germany|Leicester Royal Infirmary /ID# 15081, Leicester, England, LE1 5WW, United Kingdom Less << |
NCT02143401 | Cirrhosis Hep... More >>atitis B Infection Hepatitis C Infection Metastatic Malignant Solid Neoplasm Recurrent Hepatocellular Carcinoma Recurrent Malignant Solid Neoplasm Refractory Malignant Neoplasm Stage IV Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm Less << | Phase 1 | Recruiting | - | United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, California University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Edward J. Kim United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Sarah L. Davis United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, Iowa University of Iowa/Holden Comprehensive Cancer Center Recruiting Iowa City, Iowa, United States, 52242 Contact: Site Public Contact 800-237-1225 Principal Investigator: Mohammed M. Milhem United States, Maryland University of Maryland/Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Site Public Contact 800-888-8823 Principal Investigator: Edward A. Sausville United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, New York Columbia University/Herbert Irving Cancer Center Recruiting New York, New York, United States, 10032 Contact: Site Public Contact 212-305-6361 nr2616@cumc.columbia.edu Principal Investigator: Gulam A. Manji United States, Pennsylvania Thomas Jefferson University Hospital Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Site Public Contact 215-955-6084 Principal Investigator: James A. Posey United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Ahmed O. Kaseb Less << |
NCT03592576 | - | - | - | - | |
NCT01087151 | Chronic Lymphocytic Leukemia | Phase 2 | Completed | - | - |
NCT03181126 | Acute Lymphoblastic Leukemia (... More >>ALL) Lymphoblastic Lymphoma Less << | Phase 1 | Recruiting | June 17, 2020 | United States, California ... More >> City of Hope /ID# 169029 Recruiting Duarte, California, United States, 91010 LPCH Stanford /ID# 163337 Recruiting Palo Alto, California, United States, 94304 United States, Illinois University of Chicago /ID# 163369 Recruiting Chicago, Illinois, United States, 60637 United States, Missouri Washington University-School of Medicine /ID# 165689 Recruiting Saint Louis, Missouri, United States, 63110 United States, North Carolina Univ NC Chapel Hill /ID# 163509 Recruiting Chapel Hill, North Carolina, United States, 27514-4220 United States, Ohio Cincinnati Children's Hospital /ID# 164619 Recruiting Cincinnati, Ohio, United States, 45229 Nationwide Childrens Hospital /ID# 163372 Recruiting Columbus, Ohio, United States, 43205 United States, Oregon Oregon Health and Science University /ID# 165690 Recruiting Portland, Oregon, United States, 97239-3098 United States, Tennessee St. Jude Childrens Res Hosp /ID# 163335 Recruiting Memphis, Tennessee, United States, 38105 United States, Texas UT Southwestern Medical Center /ID# 163346 Recruiting Dallas, Texas, United States, 75390-7208 MD Anderson Cancer Center /ID# 163327 Recruiting Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin-Madiso /ID# 165691 Recruiting Madison, Wisconsin, United States, 53705 Australia, Victoria Alfred Hospital /ID# 169576 Not yet recruiting Melbourne, Victoria, Australia, 3004 Victorian Comprehensive Cancer /ID# 165710 Recruiting Melbourne, Victoria, Australia, 3050 Royal Children's Hospital /ID# 163322 Recruiting Melbourne, Victoria, Australia, 3052 Less << |
NCT00406809 | Chronic Lymphoid Leukemia|Lymp... More >>hoid Malignancies|Non-Hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Peripheral T-cell Lymphoma Less << | PHASE1|PHASE2 | COMPLETED | 2025-10-16 | Site Reference ID/Investigator... More >># 4997, Los Angeles, California, 90033, United States|Site Reference ID/Investigator# 9104, Los Angeles, California, 90095, United States|Site Reference ID/Investigator# 2613, Bethesda, Maryland, 20892, United States|Site Reference ID/Investigator# 40243, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 4745, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 2628, Buffalo, New York, 14263, United States|Site Reference ID/Investigator# 23543, New York, New York, 10016, United States|Site Reference ID/Investigator# 2627, New York, New York, 10021, United States|Site Reference ID/Investigator# 2614, New York, New York, 10032, United States|Site Reference ID/Investigator# 5383, New York, New York, 10065, United States|Site Reference ID/Investigator# 12306, Rochester, New York, 14642, United States|Site Reference ID/Investigator# 8941, Edmonton, T6G 1Z2, Canada Less << |
NCT01828476 | Prostate Cancer | Phase 2 | Terminated(The Investigator le... More >>ft the organization.) Less << | - | United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Less << |
NCT00743028 | Chronic Lymphocytic Leukemia ... More >> Lymphomas Leukemias Less << | Phase 1 | Completed | - | United States, California ... More >> Site Reference ID/Investigator# 10281 Encinitas, California, United States, 92024 Site Reference ID/Investigator# 10282 Santa Monica, California, United States, 90404 United States, Maryland Site Reference ID/Investigator# 16341 Bethesda, Maryland, United States, 20892 United States, New Hampshire Site Reference ID/Investigator# 9441 Lebanon, New Hampshire, United States, 03756 United States, New Jersey Site Reference ID/Investigator# 20041 Hackensack, New Jersey, United States, 07601 Less << |
NCT01828476 | - | Terminated(The Investigator le... More >>ft the organization.) Less << | - | - | |
NCT00888108 | Solid Tumor | Phase 1 | Completed | - | United States, Arizona ... More >> Site Reference ID/Investigator# 51982 Scottsdale, Arizona, United States, 85258 United States, Florida Site Reference ID/Investigator# 44182 Fort Lauderdale, Florida, United States, 33308 United States, Maryland Site Reference ID/Investigator# 43962 Baltimore, Maryland, United States, 21231 Netherlands Site Reference ID/Investigator# 12844 Rotterdam, Netherlands, 3015 CE Site Reference ID/Investigator# 20042 Rotterdam, Netherlands, 3015 CE United Kingdom Site Reference ID/Investigator# 12845 Surrey, United Kingdom, SM2 5PT Less << |
NCT01557777 | Chronic Lymphocytic Leukemia | PHASE2 | COMPLETED | 2025-07-13 | Site Reference ID/Investigator... More >># 74036, La Jolla, California, 92093-0698, United States|Site Reference ID/Investigator# 74035, Los Angeles, California, 90095-7059, United States|Site Reference ID/Investigator# 74038, Pleasant Hill, California, 94523, United States|Site Reference ID/Investigator# 74039, Santa Maria, California, 93454, United States|Site Reference ID/Investigator# 74033, Bethesda, Maryland, 20817, United States|Site Reference ID/Investigator# 79201, Coburg, 3058, Australia|Site Reference ID/Investigator# 78993, Greenslopes, 4120, Australia|Site Reference ID/Investigator# 77860, Afula, 18101, Israel|Site Reference ID/Investigator# 77637, Rechovot, 76100, Israel|Site Reference ID/Investigator# 77413, Gdansk, 80-952, Poland|Site Reference ID/Investigator# 79203, Ivano-Frankivsk, 76008, Ukraine|Site Reference ID/Investigator# 79205, Khmelnitsky, 29000, Ukraine|Site Reference ID/Investigator# 79202, Kyiv, 03115, Ukraine|Site Reference ID/Investigator# 79204, Lviv, 79044, Ukraine|Site Reference ID/Investigator# 79206, Poltava, 36024, Ukraine Less << |
NCT00868413 | Chronic Lymphocytic Leukemia | Phase 1 | Completed | - | United States, California ... More >> Site Reference ID/Investigator# 17841 La Jolla, California, United States, 92093 Site Reference ID/Investigator# 25899 Stanford, California, United States, 94305-5821 United States, Maryland Site Reference ID/Investigator# 21622 Baltimore, Maryland, United States, 21231-1000 United States, Ohio Site Reference ID/Investigator# 21621 Columbus, Ohio, United States, 43210 United States, Pennsylvania Site Reference ID/Investigator# 39613 Philadelphia, Pennsylvania, United States, 19111 United States, Texas Site Reference ID/Investigator# 17943 Houston, Texas, United States, 77030-4009 Less << |
NCT01121133 | Lymphoma, Including Chronic Ly... More >>mphocytic Leukemia Solid Tumors Less << | Phase 1 | Completed | - | - |
NCT00918450 | B-cell Chronic Lymphocytic Leu... More >>kemia Less << | PHASE2 | WITHDRAWN | - | - |
NCT00788684 | CD20-Positive Lymphoid Maligna... More >>ncies Chronic Lymphoid Leukemia Hematological Malignancies Non-Hodgkin's Lymphoma Less << | Phase 1 | Active, not recruiting | April 30, 2020 | United States, Arizona ... More >> University Arizona Cancer Ctr /ID# 16721 Tucson, Arizona, United States, 85719-1478 United States, California Stanford Univ School of Med /ID# 9782 Stanford, California, United States, 94305-2200 United States, Ohio Cleveland Clinic Foundation /ID# 9784 Cleveland, Ohio, United States, 44195 United States, Wisconsin Univ of Wisconsin Hosp/Clinics /ID# 21701 Madison, Wisconsin, United States, 53792-0001 Australia, Victoria Peter MacCallum Cancer Ctr /ID# 25067 Melbourne, Victoria, Australia, 3000 Royal Melbourne Hospital /ID# 9781 Parkville, Victoria, Australia, 3050 Less << |
NCT01009073 | Solid Tumors | Phase 1 | Completed | - | United States, California ... More >> Site Reference ID/Investigator# 37463 Santa Monica, California, United States, 90404 United States, Michigan Site Reference ID/Investigator# 36342 Detroit, Michigan, United States, 48201 United States, Texas Site Reference ID/Investigator# 24046 San Antonio, Texas, United States, 78229 United States, Washington Site Reference ID/Investigator# 44917 Tacoma, Washington, United States, 98405 Less << |
NCT00891605 | Solid Tumors | Phase 1 | Completed | - | - |
NCT00887757 | Solid Tumors | Phase 1 | Completed | - | - |
NCT01021358 | Lymphoma Chro... More >>nic Lymphocytic Leukemia Solid Tumors Less << | Phase 1 | Completed | - | United States, Texas ... More >> Site Reference ID/Investigator# 25068 San Antonio, Texas, United States, 78229 Less << |
NCT03222609 | Myelofibrosis (MF) | Phase 2 | Recruiting | June 11, 2021 | United States, Alabama ... More >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX Less << |
NCT00878449 | Solid Tumors | Phase 1 | Completed | - | United States, Illinois ... More >> Site Reference ID/Investigator# 13323 Chicago, Illinois, United States, 60637 Site Reference ID/Investigator# 12841 Maywood, Illinois, United States, 60153 United States, Maryland Site Reference ID/Investigator# 12303 Baltimore, Maryland, United States, 21231 United States, Massachusetts Site Reference ID/Investigator# 12305 Boston, Massachusetts, United States, 02215 Site Reference ID/Investigator# 20381 Boston, Massachusetts, United States, 02215 United States, Michigan Site Reference ID/Investigator# 43505 Detroit, Michigan, United States, 48202 United States, New Jersey Site Reference ID/Investigator# 13322 New Brunswick, New Jersey, United States, 08901 Less << |
NCT02591095 | Platinum-resistant or Refracto... More >>ry Ovarian Cancer Less << | PHASE2 | COMPLETED | 2025-03-19 | CHU Besan?on - H?pital Jean Mi... More >>njoz, Besan?on, France|Institut Bergonié, Bordeaux, France|Centre Francois Baclesse, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|CHU, Lyon, France|ICM Val d'Aurelle, Montpellier, France|ICL Institut de Cancérologie de Lorraine, Nancy, France|Centre Catherine de Sienne, Nantes, France|ICO Centre René Gauducheau, Nantes, France|ICO Paul Papin, Nantes, France|Centre Antoine LACASSAGNE, Nice, France|H?pital Européen Georges Pompidou, Paris, France|H?pital Tenon, Paris, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.03mL 0.21mL 0.10mL |
5.13mL 1.03mL 0.51mL |
10.26mL 2.05mL 1.03mL |